OR WAIT null SECS
What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
On September 8, 2026, the US Food & Drug Administration (FDA) accepted Intellia Therapeutics' Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z) and granted it Priority Review for hereditary angioedema (HAE), setting a target action date of March 10, 2027.¹
If approved, lonvo-z would become the first in vivo CRISPR-based therapy to reach the HAE market and the only 1-time treatment option for a disease currently managed with chronic prophylaxis administered as often as twice weekly.¹ This FAQ covers what the regulatory action means, what the underlying data show, and how it fits with the HAE mechanisms already approved.
A: On September 8, 2026, the FDA accepted Intellia Therapeutics' BLA for lonvo-z and granted Priority Review, setting a PDUFA target action date of March 10, 2027.¹ The FDA has also indicated it does not currently plan to hold an advisory committee meeting on the application.¹ Priority Review shortens the FDA's standard review timeline, but it is not an approval, and the therapy is not yet available to patients.
A: Lonvo-z is an in vivo CRISPR/Cas9 gene-editing therapy designed as a 1-time treatment, given as a single outpatient infusion, that inactivates the KLKB1 gene in hepatocytes to permanently lower kallikrein and downstream bradykinin production.2 Because it edits the gene directly rather than suppressing its output with an ongoing drug, the goal is durable attack prevention without continued dosing, a fundamentally different approach from every currently approved prophylactic option.2
A: HAELO was a randomized, double-blind, placebo-controlled trial enrolling 80 patients aged ≥ 16 years with type 1 or type 2 HAE. In total, 52 received lonvo-z and 28 received placebo.²
Over the 6-month primary efficacy period, lonvo-z produced an 87% reduction in mean monthly attack rate compared with placebo, 0.26 versus 2.10 attacks per month.2 62% of patients with lonvo-z were attack-free during that period.
A: Later data presented at the EAACI 2026 congress showed a 91% reduction in moderate-to-severe attacks and an 89% reduction in attacks requiring on-demand treatment, with no non-responders across the treatment arm.3 Patients also reported a 17.04-point improvement in Angioedema Quality of Life scores, well above the 6-point threshold considered clinically meaningful, and treatment-emergent adverse events were mild to moderate, with no liver toxicity observed.3
A: For a disease currently managed with chronic prophylaxis, injected as often as twice weekly for some agents, a single infusion that could eliminate the need for ongoing treatment entirely is a meaningfully different proposition than choosing between prophylactic mechanisms.¹
Lead investigator Aleena Banerji, MD, called it a "really exciting advance for our patients with hereditary angioedema” in an interview with HCPLive, while noting that with 11 treatments already available in the US, lonvo-z would add another distinct option rather than replace the need for individualized, shared decision-making.4
A: The primary efficacy period was 6 months, so durability beyond that window and long-term safety after a permanent genomic modification remain to be established through longer follow-up.² The trial's design, which required patients to discontinue prophylaxis before treatment, also raises questions about how the results translate to real-world patients who may be reluctant to stop an existing regimen to start a 1-time, irreversible therapy.²
Lonvo-z isn't arriving at an empty field. Three other HAE therapies, across 3 distinct mechanisms, were approved in 2025, and an updated guideline has since named sebtralstat first-line for on-demand treatment.5
A: Garadacimab-gxii (Andembry), approved in June 2025, is a monthly injectable monoclonal antibody targeting factor XIIa for prophylaxis.6 Donidalorsen (Dawnzera), approved in August 2025, is an antisense oligonucleotide dosed every 4 to 8 weeks, also for prophylaxis.⁷ Sebetralstat (Ekterly), approved in July 2025, is the first oral, on-demand therapy for acute attacks, and an updated pediatric guideline now recommends it as first-line on-demand therapy for adolescents 12 and older.5,8
Other treatments include icatibant, ecallantide, C1-INH, lanadelumab, and attenuated androgens.9
A: No. Lonvo-z remains investigational; the FDA's PDUFA target action date is March 10, 2027, and approval is not guaranteed.¹ Patients should continue their current prophylactic or on-demand regimen, and clinicians shouldn't set expectations around availability before a decision is made.
A: Any patient curious about emerging options, or any patient not well-controlled on current therapy, is a reasonable referral regardless of lonvo-z's regulatory status.
This FAQ reflects the regulatory status of lonvoguran ziclumeran and the broader HAE treatment landscape as of September 2026. Lonvo-z is investigational and not yet FDA-approved; its PDUFA target action date is March 10, 2027.
References
